Scientists Win $3M Breakthrough Prize for Sickle Cell and Beta Thalassemia Cure

Dr. Swee Lay Thein and Dr. Stuart Orkin have been awarded the $3 million Breakthrough Prize in Life Sciences for their pioneering work that led to the first approved CRISPR-based gene-editing therapy for sickle cell disease, a breakthrough that also holds promise for treating beta thalassemia.

The prize, announced in April 2026, recognizes their decades-long research into fetal hemoglobin regulation, which laid the scientific foundation for exa-cel (exagamglogene autotemcel), the first CRISPR gene-editing therapy approved by the U.S. Food and Drug Administration in December 2023 for the treatment of severe sickle cell disease in patients aged 12 and older.

Dr. Thein, a hematologist at the University of California, San Francisco, and Dr. Orkin, a pediatric oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, independently and collaboratively identified the BCL11A gene as a key suppressor of fetal hemoglobin production after birth. Their work demonstrated that inhibiting BCL11A could reactivate fetal hemoglobin, which compensates for defective adult hemoglobin in sickle cell disease and beta thalassemia.

This insight directly enabled the development of exa-cel, a one-time therapy in which a patient’s hematopoietic stem cells are edited using CRISPR-Cas9 to disrupt the BCL11A enhancer region, thereby increasing fetal hemoglobin production. Clinical trials showed that nearly all treated patients experienced elimination of vaso-occlusive crises — the painful hallmark of sickle cell disease — and sustained increases in fetal hemoglobin levels without the need for ongoing immunosuppressive therapy.

The FDA’s approval of exa-cel marked a historic milestone as the first CRISPR-based therapy authorized for any genetic disease. In clinical studies, 94% of patients remained free of severe vaso-occlusive crises for at least 12 months post-treatment, and hemoglobin levels normalized in most cases. Long-term follow-up data continue to show durable responses, with no evidence of off-target effects or malignancy to date.

While the therapy is currently approved only for sickle cell disease, researchers believe the same approach could be adapted for beta thalassemia, another inherited blood disorder caused by insufficient or abnormal hemoglobin production. Early-stage trials are underway to assess exa-cel’s efficacy in transfusion-dependent beta thalassemia patients, with preliminary results showing similar increases in fetal hemoglobin and reduced transfusion requirements.

Despite its promise, exa-cel remains limited by high cost and complex delivery requirements. The treatment involves chemotherapy to clear the bone marrow, followed by infusion of edited stem cells, necessitating specialized medical centers and prolonged hospitalization. The list price exceeds $2 million per patient, raising concerns about accessibility, particularly in low- and middle-income countries where the burden of sickle cell disease is highest.

Experts emphasize that while the therapy is curative for many, long-term monitoring is essential to assess potential late effects. The Breakthrough Prize selection committee cited the duo’s work as a transformative advance in genetic medicine, noting that it represents one of the first successful translations of CRISPR technology from laboratory discovery to routine clinical use.

Dr. Orkin has previously received numerous accolades for his contributions to hematology and genetics, including the Lasker Award. Dr. Thein’s research has focused on hemoglobin switching and global health disparities in hemoglobinopathies. Together, their work has not only advanced scientific understanding but also catalyzed a new era of curative therapies for genetic blood disorders.

As of 2026, over 200 patients have received exa-cel in clinical trials or through approved treatment programs. Ongoing studies are evaluating younger pediatric populations and exploring in vivo gene-editing approaches that could eliminate the need for stem cell collection and chemotherapy conditioning.

The Breakthrough Prize, founded in 2012 by Sergey Brin, Priscilla Chan, Mark Zuckerberg, Yuri Milner, and Anne Wojcicki, awards $3 million in each category to recognize transformative advances in life sciences, fundamental physics, and mathematics. The 2026 award in Life Sciences underscores the growing impact of precision gene-editing technologies in treating previously intractable genetic diseases.